Mainz BioMed NV News - MYNZ

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today increasing demand from existing and prospective laboratory partners for its enhanced ColoAlert product that has been launched in July 2024 and is currently being commercialized across Europe and in select international markets. This advanced version of the Company’s colorectal cancer (CRC) screening test is set to become the standard offering for all existing partners, reflecting its proven benefits in optimizing screening efficiency and improving user experience.
Widespread Transition to Enhanced ColoAlert

One of the earliest partners to make the transition is GANZIMMUN Diagnostics, one of Germany’s premier laboratories, which licensed the ColoAlert test. GANZIMMUN will fully implement the enhanced version of the innovative DNA biomarker-based screening product by the beginning of next year, taking advantage of the significant improvements in sample processing and usability that have set a new industry benchmark.

Improving Customer Interest

Partners are particularly drawn to the enhanced features, such as the proprietary DNA stabilizing buffer that ensures reliable results despite varying sample volumes, and the streamlined collection devices that simplify at-home testing for users. These innovations have drastically reduced the need for retesting, offering faster turnaround times for patients, with results available in just 2–3 days from sample arrival.

Promotion at Key Medical Event

GANZIMMUN Diagnostics will showcase the enhanced ColoAlert at the 57th Medizinische Woche Baden-Baden, a medical congress in Germany focusing on complementary medicine, which takes place from October 30 to November 3, 2024. This underscores the increasing role of complementary medicine in cancer prevention and early detection. The event will provide an ideal platform to promote Mainz Biomed’s innovative DNA-based CRC screening test to medical professionals, integrative medicine practitioners, and researchers interested in advanced diagnostic solutions.
"We are excited to support GANZIMMUN in introducing the enhanced ColoAlert at such a prestigious event," stated Tarrin Khairi-Taraki, VP Commercial Operations at Mainz Biomed. "The 57th Medizinische Woche Baden-Baden provides an excellent opportunity to demonstrate the importance of early colorectal cancer detection and how our innovations are making this process more efficient."

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Mainz BioMed NV (MYNZ)

Professional-Grade Tools, for Individual Investors.

MYNZ News

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mainz Biomed Reports Results of 2024 Annual General Meeting

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Form D/A - Notice of Exempt Offering of Securities: [Amend]

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Mainz Biomed Reports Full Year 2023 Financial Results

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

MYNZ Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists